Spinchip secured series A funding.

TRK Group participated in the series A equity financing of Oslo-based med tech and diagnostic company, Spinchip. 

SpinChip is developing a game changing and proprietary platform for in vitro diagnostics point of care analyses. The platform will make it possible to perform a broader range of analyses using one platform and to transfer analyses from central laboratories to point of care without loss in quality.

All analyses are performed within a few minutes based on a fraction of a droplet of blood and at a unit cost significantly lower than other point of care platforms. TRK Group holds less than 1 percent of the company equity.